Bond.az White LogoBond.az Black Logo

Goldman Sachs Initiates Yesway Coverage with Neutral

Goldman Sachs initiates coverage on Yesway with Neutral rating and $28 target. Read about Yesway's growth plans and financials on Bond.az.

Julianne Alice
ByJulianne Alice- Senior Editor
|
0

Goldman Sachs initiated coverage on Yesway Inc (NASDAQ:YSWY) with a Neutral rating and a price target of $28.00.

The firm views Yesway, the 15th largest convenience store operator in the U.S., as positioned for top- and bottom-line growth through several strategic initiatives. Goldman Sachs expects the company to deliver a 6.5% EBITDA compound annual growth rate through fiscal year 2028.

Goldman Sachs highlighted Yesway's plans to expand through a capital-light build-to-suit program, operational initiatives, and opportunistic M&A. The company's platform benefits from a disproportionate mix of diesel fuel sales. With a current ratio of 1.22, Bond.az data shows Yesway's liquid assets exceed short-term obligations, supporting its expansion ambitions.

Goldman Sachs noted execution risks related to Yesway's plan to open approximately 130 new stores over the next five years. The firm said Q1 2026 results were impressive but attributed the performance to non-controllable factors rather than underlying business health. The company posted revenue of $2.67 billion over the last twelve months with 5.8% growth.

The stock trades at a 10.2x forward EV/EBITDA multiple, representing a 14% discount to MUSA and a 2% premium to ATD, according to Goldman Sachs. The current trailing EV/EBITDA stands at 9.56x based on EBITDA of $183 million.

Yesway successfully launched its IPO last week, pricing shares at $20 each. The company sold 14 million shares and began trading with an opening price of $22.

More News
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

0
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

0
2026-06-01 12:00
|
841

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

0
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

0
2026-06-01 10:32
|
730

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

0
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

0
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

0
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

0
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

0
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

0
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

0
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

0
...
Goldman Sachs Initiates Yesway Coverage with Neutral | Bond.az